XBiotech completed a groundbreaking clinical study in cardiovascular medicine. This Phase II randomized, multi-center clinical study evaluated a True Human™ therapeutic antibody MABp1 for its ability to reduce adverse events after balloon angioplasty, atherectomy, or stent placement in patients undergoing revascularization procedures for blockage of a major artery. This drug development program has U.S. FDA Fast Track designation.
Vascular disease is currently one of the most common causes of death in both developed countries and emerging economic regions. While there has been significant research, technology has largely centered around angioplasty and the use of stents to open affected arteries and maintain patency, respectively.